JAMA Drug Pricing Studies: Moving The Needle Or Looking At The Past?
Studies show net prices increases, R&D spending lower than often cited, and better profit margins other industries. But pharma pushes back with concerns about study designs and maintains the picture has changed in more recent years.
You may also be interested in...
The US government has a routine approach for negotiating single-seller/single-buyer contracts, but drug pricing politics and public fears of coronavirus will likely complicate any purchasing talks with a sponsor, should an effective vaccine or therapeutic emerge.
Over the past 20 years, the pharmaceutical industry has notched a series of wins with its extraordinary federal lobbying expenditures and campaign contributions. A new JAMA Internal Medicine study examines spending from 1999-2018.
Research published in JAMA shows that the pharmaceutical industry outpaces other industries in the S&P 500 on several measures of profitability.